ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER (ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER).
Ceftriaxone is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
| Metabolism | Ceftriaxone is not metabolized; it is excreted unchanged primarily in urine (50-60%) and bile (40-50%). |
| Excretion | Renal (33-67% unchanged) and biliary (40-50% unchanged and microbiologically inactive metabolite). Approximately 50% excreted in urine, 50% in feces. |
| Half-life | Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged up to 15 hours in elderly; significantly increased in renal impairment (up to 20-30 hours in ESRD). |
| Protein binding | Protein binding: ~85-95%, primarily to albumin. Binding is saturable and decreases with higher concentrations. |
| Volume of Distribution | Volume of distribution: 0.12-0.14 L/kg (7-10 L in adults), indicating primarily extracellular distribution. Higher Vd in neonates (0.3-0.5 L/kg). |
| Bioavailability | Bioavailability: IM administration: 100% (due to complete absorption). |
| Onset of Action | IV: Rapid, within 15-30 minutes. IM: 1-2 hours. |
| Duration of Action | Duration: Approximately 24 hours due to long half-life, allowing once-daily dosing for most infections. Clinical effect persists for 24 hours. |
| Molecular Weight | 554.58 |
1-2 g IV or IM once daily; maximum 4 g/day. For serious infections, 2 g IV every 12 hours.
| Dosage form | INJECTABLE |
| Renal impairment | No adjustment required for GFR >5 mL/min. For GFR <5 mL/min (including dialysis), maximum dose 2 g/day. |
| Liver impairment | No adjustment recommended for Child-Pugh Class A or B. For Child-Pugh Class C, use with caution; no specific dosage guidelines. |
| Pediatric use | 50-75 mg/kg/day IV/IM once daily; maximum 2 g/day. For meningitis, 100 mg/kg/day once daily (max 4 g/day). |
| Geriatric use | No specific adjustment; use lowest effective dose based on renal function. Monitoring of renal function recommended. |
| 1st trimester | Ceftriaxone crosses the placenta and is classified as pregnancy category B. No evidence of fetal harm in animal studies; limited human data. Use only if clearly needed. |
| 2nd trimester | Generally considered safe; no known teratogenic risk. Use for infections requiring cephalosporin therapy. |
| 3rd trimester | Safe; may cause displacement of bilirubin from albumin in neonates if given near delivery. Use with caution in women with hyperbilirubinemic newborns. |
Clinical note
Comprehensive clinical and safety monograph for ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER (ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER).
| Placental transfer | Crosses placenta readily; achieves therapeutic concentrations in fetal tissues and fluids. Approximately 10-15% of maternal serum levels. |
| Breastfeeding | Ceftriaxone is excreted into breast milk in low concentrations (approximately 2-4% of maternal dose). No known adverse effects in nursing infants. Compatible with breastfeeding. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to ceftriaxone or any cephalosporinHyperbilirubinemic neonates (especially premature) due to risk of bilirubin encephalopathyUse with intravenous calcium in neonates (<28 days) due to risk of precipitation
| Precautions | Hypersensitivity reactions including anaphylaxis, Clostridioides difficile-associated diarrhea, Hemolytic anemia, Biliary pseudolithiasis and pancreatitis, Superinfection, Neuromuscular blockade in myasthenia gravis, Seizures with high doses or renal impairment |
| Food/Dietary | No specific food restrictions. However, avoid alcohol (ethanol) during therapy and for 48 hours after discontinuation due to potential disulfiram-like reaction (nausea, vomiting, headache, flushing). |
Loading safety data…
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Ceftriaxone (Rocephin) is FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. In humans, no adequate controlled studies in pregnant women exist. However, ceftriaxone crosses the placenta. First trimester: Theoretical risk of kernicterus in neonates due to bilirubin displacement, but not confirmed. Second and third trimesters: Use only if clearly needed; risk of biliary sludging in mother and neonate, but no known teratogenicity. |
| Fetal Monitoring | Maternal: Renal function, hepatic function, and CBC with differential during prolonged therapy; signs of superinfection or allergic reactions. Fetal/Neonatal: No specific monitoring required, but if used near term, observe neonate for signs of kernicterus (jaundice, lethargy) or biliary sludging (abdominal distension, vomiting). |
| Fertility Effects | No known adverse effects on human fertility. Animal studies have not shown impaired fertility at clinically relevant doses. |
| Clinical Pearls | ROCEPHIN (ceftriaxone) is a third-generation cephalosporin with broad-spectrum coverage, including gram-negative bacteria, some gram-positive, and anaerobes. It has a long half-life permitting once-daily dosing. Do not co-administer with calcium-containing IV solutions in neonates due to risk of ceftriaxone-calcium precipitation; avoid within 48 hours of each other. Monitor for hypersensitivity reactions, especially in penicillin-allergic patients (cross-reactivity ~10%). Use with caution in patients with biliary obstruction or gallbladder disease due to possible ceftriaxone sludge. Adjust dose in severe renal impairment (CrCl <10 mL/min) to 2 g max daily. |
| Patient Advice | This medication is given as an intravenous infusion; do not mix with calcium-containing solutions. · Report any signs of allergic reaction (rash, itching, swelling, difficulty breathing) immediately. · You may experience diarrhea, nausea, or injection site pain; inform your healthcare provider if severe. · Avoid alcohol consumption during treatment and for at least 48 hours after the last dose to prevent disulfiram-like reactions. · Notify your doctor if you have a history of gallbladder problems or if you develop right upper abdominal pain. |